3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
27
Terminated
9
Withdrawn
5
Unknown
2
Active not recruiting
2
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
25
Burkitt Lymphoma
13
Leukemia, Biphenotypic, Acute
9
Leukemia, Myeloid, Acute
6
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Osteosarcoma
3
Myelodysplastic Syndromes
3
Lymphoma
3
Breast Neoplasms
3
Blastic Plasmacytoid Dendritic Cell Neoplasm
3
Primary Myelofibrosis
2
Neoplasm Metastasis
2
Myeloproliferative Disorders
2
Lymphoma, T-Cell
2
Lymphoma, Non-Hodgkin
2
Leukemia, Large Granular Lymphocytic
2
Leukemia
2
Hematologic Neoplasms
2
Urinary Bladder Neoplasms
1
Thrombocythemia, Essential
1
Sarcoma, Ewing
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Recurrence
1
Polycythemia Vera
1
Pathologic Complete Response
1
Oropharyngeal Neoplasms
1
Neoplasm, Residual
1
Myelodysplastic-Myeloproliferative Diseases
1
Mouth Neoplasms
1
Interventions
Cyclophosphamide
10
fludarabine
6
Tacrolimus
5
Mycophenolic Acid
5
Melphalan
4
ruxolitinib
3
Whole-Body Irradiation
3
Thiotepa
3
Busulfan
3
thymoglobulin
2
fludarabine phosphate
2
Stem Cell Transplantation
2
Specimen Handling
2
Clofarabine
2
Biopsy
2
vedolizumab
1
belumosudil
1
Tomography, Optical Coherence
1
Sirolimus
1
Radiotherapy
1
Radiation
1
Prednisone
1
Methotrexate
1
Mesna
1
Low-Level Light Therapy
1
LDP-02
1
Immunoglobulin G
1
Hematopoietic Stem Cell Transplantation
1
Fecal Microbiota Transplantation
1
Emapalumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Graft vs Host Disease
×
Methotrexate
×
Clear all
NCT06252870
2026-01-26
CY-MET-RIC
Nantes University Hospital
Phase 2
Recruiting
82 enrolled